WallStreetZenWallStreetZen

NASDAQ: ALNY
Alnylam Pharmaceuticals Inc Stock Ownership - Who owns Alnylam Pharmaceuticals?

Insider buying vs selling

Have Alnylam Pharmaceuticals Inc insiders been buying or selling?
Buy
Sell
NameRoleDateSharesPriceValue
Yvonne GreenstreetChief Executive Officer2024-08-2015,000$85.00
$1.28MBuy
Yvonne GreenstreetChief Executive Officer2024-08-2015,000$280.00
$4.20MSell
Kevin Joseph FitzgeraldCSO EVP Head of Research2024-08-121,158$273.73
$316.98kSell
Kevin Joseph FitzgeraldCSO EVP Head of Research2024-08-123,913$272.43
$1.07MSell
Kevin Joseph FitzgeraldCSO EVP Head of Research2024-08-125,736$271.32
$1.56MSell
Kevin Joseph FitzgeraldCSO EVP Head of Research2024-08-129,662$270.17
$2.61MSell
Kevin Joseph FitzgeraldCSO EVP Head of Research2024-08-121,421$268.66
$381.77kSell
Kevin Joseph FitzgeraldCSO EVP Head of Research2024-08-1214,058$85.00
$1.19MBuy
Kevin Joseph FitzgeraldCSO EVP Head of Research2024-08-126,667$97.72
$651.50kBuy
Kevin Joseph FitzgeraldCSO EVP Head of Research2024-08-12135$274.65
$37.08kSell

1 of 15

ALNY insiders have sold more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when ALNY insiders and whales buy or sell their stock.

ALNY Shareholders

What type of owners hold Alnylam Pharmaceuticals Inc stock?
Institutional
Insider
Retail
NameHoldSharesValueType
Capital World Investors11.66%14,971,343$4.24BInstitution
Ag Novartis11.53%14,800,620$4.19BInsider
Vanguard Group Inc9.74%12,507,778$3.54BInstitution
Fmr LLC9.47%12,164,038$3.45BInstitution
Sanofi8.22%10,554,134$2.99BInsider
Blackrock Inc7.44%9,547,663$2.71BInstitution
Wellington Management Group LLP4.84%6,210,479$1.76BInstitution
Baillie Gifford Co4.70%6,032,656$1.71BInstitution
Capital International Investors3.03%3,891,059$1.10BInstitution
Dodge Cox2.94%3,780,185$1.07BInstitution

1 of 3

ALNY vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
ALNY81.25%18.75%Net SellingNet Selling
ARGX57.27%0.00%
BNTX17.23%0.00%
BGNE3.39%34.20%Net SellingNet Selling
MRNA68.21%22.78%Net SellingNet Selling

Alnylam Pharmaceuticals Stock Ownership FAQ

Who owns Alnylam Pharmaceuticals?

Alnylam Pharmaceuticals (NASDAQ: ALNY) is owned by 93.41% institutional shareholders, 21.55% Alnylam Pharmaceuticals insiders, and 0.00% retail investors. Ag Novartis is the largest individual Alnylam Pharmaceuticals shareholder, owning 14.80M shares representing 11.53% of the company. Ag Novartis's Alnylam Pharmaceuticals shares are currently valued at $4.25B.

If you're new to stock investing, here's how to buy Alnylam Pharmaceuticals stock.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.